N-Side
Financials
Estimates*
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Revenues | - | 8.1m | 12.3m | 14.4m | 18.2m | 23.7m |
% growth | - | - | 52 % | 17 % | 27 % | 30 % |
EBITDA | 1.3m | 3.3m | 4.4m | 3.7m | 2.2m | - |
% EBITDA margin | - | 41 % | 35 % | 26 % | 12 % | - |
Profit | <1m | <1m | 2.0m | <1m | (2.4m) | <1m |
% profit margin | - | 12 % | 16 % | 2 % | (13 %) | 4 % |
Date | Investors | Amount | Round |
---|---|---|---|
€10.0m | Angel | ||
* | €2.7m Valuation: €50.0m | Late VC | |
* | €3.2m | Debt | |
Total Funding | €12.7m |
Recent News about N-Side
EditN-SIDE is a technology company specializing in advanced software solutions for clinical supply chain management. Operating in the life sciences sector, N-SIDE serves pharmaceutical companies and clinical research organizations by providing tools that optimize clinical supply planning and risk management. Their software ensures that medications are delivered on time, regardless of trial complexity, by offering unprecedented visibility, control, and reliability. The company leverages advanced analytics and machine learning to forecast and optimize clinical trials, thereby reducing risks and accelerating time-to-market for critical medications. N-SIDE's business model revolves around selling software licenses and providing consulting services to its clients. The company generates revenue through subscription fees and professional services.
Keywords: clinical supply planning, risk management, life sciences, pharmaceutical, advanced analytics, machine learning, software solutions, clinical trials, supply chain, optimization.